Revenue Breakdown
Composition ()
No data
Revenue Streams
Ironwood Pharmaceuticals Inc (IRWD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Human Therapeutics, accounting for 83.8% of total sales, equivalent to $9.19M. Another important revenue stream is Biomanufacturing. Understanding this composition is critical for investors evaluating how IRWD navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Ironwood Pharmaceuticals Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.74%, while the net margin is -4.77%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IRWD converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IRWD competes directly with industry leaders such as FULC and LXRX. With a market capitalization of $582.12M, it holds a significant position in the sector. When comparing efficiency, IRWD's gross margin of 100.00% stands against FULC's N/A and LXRX's 99.93%. Such benchmarking helps identify whether Ironwood Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
